138 related articles for article (PubMed ID: 37706451)
1. Immune-mediated colitis associated with ocrelizumab: A new safety risk.
Kim T; Brinker A; Croteau D; Lee PR; Baldassari LE; Stevens J; Hughes A; Tomaino J; deFonseka A; Altepeter T; Kortepeter CM
Mult Scler; 2023 Sep; 29(10):1275-1281. PubMed ID: 37706451
[TBL] [Abstract][Full Text] [Related]
2. Histologic manifestations of ocrelizumab-associated intestinal and hepatic injury in patients with multiple sclerosis.
Challa B; Esnakula AK
Histopathology; 2024 Apr; 84(5):765-775. PubMed ID: 38114289
[TBL] [Abstract][Full Text] [Related]
3. Adverse event profile differences between rituximab and ocrelizumab: Findings from the FDA Adverse Event Reporting Database.
Caldito NG; Shirani A; Salter A; Stuve O
Mult Scler; 2021 Jun; 27(7):1066-1076. PubMed ID: 32820687
[TBL] [Abstract][Full Text] [Related]
4. The Safety Profile of Vedolizumab in Ulcerative Colitis and Crohn's Disease: 4 Years of Global Post-marketing Data.
Cohen RD; Bhayat F; Blake A; Travis S
J Crohns Colitis; 2020 Feb; 14(2):192-204. PubMed ID: 31504340
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD20 monoclonal antibody (mAb) therapy and colitis: A case series and review.
Tolaymat S; Sharma K; Kagzi Y; Sriwastava S
Mult Scler Relat Disord; 2023 Jul; 75():104763. PubMed ID: 37229799
[TBL] [Abstract][Full Text] [Related]
6. Colitis following the use of immune checkpoint inhibitors: A real-world analysis of spontaneous reports submitted to the FDA adverse event reporting system.
Hu Y; Gong J; Zhang L; Li X; Li X; Zhao B; Hai X
Int Immunopharmacol; 2020 Jul; 84():106601. PubMed ID: 32422528
[TBL] [Abstract][Full Text] [Related]
7. Colitis associated with biological agents.
Freeman HJ
World J Gastroenterol; 2012 Apr; 18(16):1871-4. PubMed ID: 22563166
[TBL] [Abstract][Full Text] [Related]
8. Birth outcome in women with ulcerative colitis and Crohn's disease, and pharmacoepidemiological aspects of anti-inflammatory drug therapy.
Nørgård BM
Dan Med Bull; 2011 Dec; 58(12):B4360. PubMed ID: 22142578
[TBL] [Abstract][Full Text] [Related]
9. IL-17 Inhibitors and Inflammatory Bowel Diseases: A Postmarketing Study in Vigibase.
Petitpain N; D'Amico F; Yelehe-Okouma M; Jouzeau JY; Netter P; Peyrin-Biroulet L; Gillet P
Clin Pharmacol Ther; 2021 Jul; 110(1):159-168. PubMed ID: 33411953
[TBL] [Abstract][Full Text] [Related]
10. Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies.
Ali AK; Watson DE
Pharmacotherapy; 2017 Nov; 37(11):1383-1390. PubMed ID: 28950039
[TBL] [Abstract][Full Text] [Related]
11. Ulcerative colitis exacerbation after the onset of immune checkpoint inhibitor related colitis.
Kayashima A; Shimozaki K; Hirata K; Mutaguchi M; Takabayashi K; Hayashi Y; Hosoe N; Ogata H; Sujino T; Kanai T
Clin J Gastroenterol; 2021 Feb; 14(1):152-158. PubMed ID: 33058056
[TBL] [Abstract][Full Text] [Related]
12. Real-world experience of ocrelizumab initiation in a diverse multiple sclerosis population.
Coban H; Germaine S; Dimaandal I; Haberli N; Padam C; Creed MA; Imitola J
Mult Scler Relat Disord; 2021 Aug; 53():103021. PubMed ID: 34077828
[TBL] [Abstract][Full Text] [Related]
13. Ocrelizumab-induced colitis and cytomegalovirus infection and their disadvantageous interaction with underlying multiple sclerosis.
Lieb S; Heni M; Rauschenberg S; Lange K; Feisthammel J; Bläker H; Wiegand J
Z Gastroenterol; 2023 Nov; 61(11):1500-1503. PubMed ID: 36736346
[TBL] [Abstract][Full Text] [Related]
14. Vedolizumab for the treatment of ulcerative colitis and Crohn's disease.
McLean LP; Shea-Donohue T; Cross RK
Immunotherapy; 2012 Sep; 4(9):883-98. PubMed ID: 23046232
[TBL] [Abstract][Full Text] [Related]
15. Refractory fulminant colitis following ocrelizumab therapy requiring colectomy in a patient with multiple sclerosis.
Malloy R; Fernandes R; Begun J; An YK
BMJ Case Rep; 2022 Dec; 15(12):. PubMed ID: 36517079
[TBL] [Abstract][Full Text] [Related]
16. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis.
Peyrin-Biroulet L; Arkkila P; Armuzzi A; Danese S; Guardiola J; Jahnsen J; Lees C; Louis E; Lukáš M; Reinisch W; Roblin X; Jang M; Byun HG; Kim DH; Lee SJ; Atreya R
BMC Gastroenterol; 2022 Jun; 22(1):291. PubMed ID: 35676620
[TBL] [Abstract][Full Text] [Related]
17. Ocrelizumab Treatment in Patients with Primary Progressive Multiple Sclerosis: Short-term Safety Results from a Compassionate Use Programme in Germany.
Rauer S; Hoshi MM; Pul R; Wahl M; Schwab M; Haas J; Ellrichmann G; Krumbholz M; Tackenberg B; Saum KU; Buck F; Leemhuis J; Kretschmann A; Aktas O
Clin Neurol Neurosurg; 2020 Oct; 197():106142. PubMed ID: 32920498
[TBL] [Abstract][Full Text] [Related]
18. Crohn's-like disease in a patient exposed to anti-Interleukin-17 blockade (Ixekizumab) for the treatment of chronic plaque psoriasis: a case report.
Smith MK; Pai J; Panaccione R; Beck P; Ferraz JG; Jijon H
BMC Gastroenterol; 2019 Sep; 19(1):162. PubMed ID: 31488067
[TBL] [Abstract][Full Text] [Related]
19. Real-world Effectiveness and Safety of Vedolizumab for the Treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort.
Plevris N; Chuah CS; Allen RM; Arnott ID; Brennan PN; Chaudhary S; Churchhouse AMD; Din S; Donoghue E; Gaya DR; Groome M; Jafferbhoy HM; Jenkinson PW; Lam WL; Lyons M; Macdonald JC; MacMaster M; Mowat C; Naismith GD; Potts LF; Saffouri E; Seenan JP; Sengupta A; Shasi P; Sutherland DI; Todd JA; Veryan J; Watson AJM; Watts DA; Jones GR; Lees CW
J Crohns Colitis; 2019 Sep; 13(9):1111-1120. PubMed ID: 30768123
[TBL] [Abstract][Full Text] [Related]
20. Pharmacodynamic assessment of vedolizumab for the treatment of ulcerative colitis.
McLean LP; Cross RK
Expert Opin Drug Metab Toxicol; 2016 Jul; 12(7):833-42. PubMed ID: 27096357
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
